2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Value, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6028 Late relapse after allogeneic hematopoietic cell transplantation for myeloid malignancy is rare and driven by distinct factors

Jason Sean Gilbert, MD, Megan Othus, PhD2, Kathryn (Katie) D. Russell, ARNP3, Gary Schoch4, Chris Davis5, Ryan Basom6, Marco Mielcarek, MD7, Mary-Elizabeth Percival, MD8
1 University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Background:
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Recurrence of malignancy most commonly occurs within the first year post-HCT. Rarely, myeloid malignancies relapse several years after HCT, and risk factors for late relapse are poorly understood. This is further complicated by the difficulty in distinguishing true relapse from a new therapy-related or donor cell leukemia. We sought to characterize patients with myeloid malignancies who experienced relapse ≥2 years after allogeneic HCT to better define risk factors associated with late relapse.

Methods:
Using an IRB-approved institutional database, we retrospectively reviewed all patients with MDS and AML who had allogeneic HCT at Fred Hutchinson Cancer Center between 1969 and 2025. Descriptive analyses were performed for patients experiencing relapse ≥2 years post-HCT. Among patients alive and relapse-free two years post-HCT, relapse risk was evaluated using univariate and multivariable cause-specific hazard models (death prior to relapse considered a competing risk), with the multivariable model adjusted for age at HCT, sex, diagnosis, donor type, acute and chronic graft-versus-host-disease (GVHD), and GVHD-directed treatment with systemic corticosteroids.

Results:
A total of 4791 patients with myeloid malignancies had allogeneic HCT during this timeframe (median age 50.0 years, range 18.0-80.9; 45% female; 66% AML). Donor types consisted of 40% HLA-matched related, 34% HLA-matched unrelated, 18% mismatched, 5% cord blood, and 3% haploidentical, and this distribution varied by transplant era. Overall, 1339 (28%) patients relapsed: ≤1 year, N=1002 (75%); 1-2 years, N=143 (11%); ≥2 years, N=194 (14%); ≥5 years, N=66 (5%). The latest relapse occurred 33.9 years post-HCT.

In a landmark analysis including 2066 patients alive and relapse-free at two years, older age at HCT was independently associated with increased relapse risk (HR 1.04 per year of age, 95% CI 1.03-1.05). MDS was associated with a lower risk of relapse compared with AML in multivariable (HR 0.71, 95% CI 0.56-0.90) but not univariate analysis (HR 0.88, 95% CI 0.70-1.10). HCT in the 2000s (vs. 1970s) was associated with decreased relapse only in multivariable analysis (HR 0.43, 95% CI 0.19-0.98), but not in univariate analysis (HR 0.83, 95% CI 0.38-1.80). Patient sex, donor type, acute and chronic GVHD, and GVHD-directed treatment with systemic corticosteroids were not associated with increased relapse risk.

Among the 66 patients who relapsed ≥5 years post-HCT, extramedullary disease was found in 8 of the 35 (23%) evaluable patients, and donor cell leukemia was identified in 3 of the 22 (14%) patients who had chimerism testing available. Given changes in our ability to genomically characterize malignancies over the large study period, only four patients had cytogenetic and molecular data for both baseline and relapsed disease, and all four retained features of their original clone, consistent with relapse rather than a new myeloid malignancy.

Conclusions:
The risk of post-HCT relapse is highly time-dependent, with only 14% of relapses occurring ≥2 years post-HCT. GVHD incidence and treatment, along with donor type, are known to modulate the graft-versus-leukemia (GVL) effect, but they were not associated with relapse risk in our cohort. In contrast, increased recipient age at HCT, possibly via age-related blunting of the GVL effect, showed a robust association. These findings suggest that the biology driving late relapse may be distinct from that of early relapse. Further, among patients with very late relapse (≥5 years post-HCT), both extramedullary disease and donor cell leukemia were relatively frequent. Although data were limited, we found no molecular evidence of a secondary myeloid malignancy initially misinterpreted as primary disease recurrence. Other limitations include incomplete follow up and documentation regarding cause of death. Nonetheless, these findings support counseling long-term survivors that relapse risk, while persisting for decades, remains very low. Incorporating these findings into a late-relapse risk model could help identify patients who would benefit from extended post-HCT surveillance.

Jason Sean Gilbert, MD: No relevant conflicts of interest to declare.